OverviewSuggest Edit

Astellas Pharma is a pharmaceutical company focused on the development of drugs and medical solutions. Its focus areas include urology, immunology, cardiology, infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. Astellas Pharma's main products include XTANDI, an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation-positive; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); Evrenzo, an oral treatment for anemia associated with chronic kidney disease (CKD), and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used to suppress organ rejection following a transplant.

TypePublic
Founded1923
HQTokyo, JP
Websiteastellas.com
Employee Ratings3.1
Overall CultureF

Latest Updates

Employees (est.) (Mar 2020)15,883(-2%)
Job Openings84
Revenue (FY, 2020)¥1.3 T
Share Price (Jul 2021)¥1.9 K
Cybersecurity ratingBMore

Key People/Management at Astellas Pharma

Yoshihiko Hatanaka

Yoshihiko Hatanaka

Representative Director, Chairman of the Board
Shontelle Dodson

Shontelle Dodson

Senior Vice President and Head of US Medical Specialties Business Unit
Kenji Yasukawa

Kenji Yasukawa

Representative Director, President and CEO
Lynn Fenicchia

Lynn Fenicchia

Senior Vice President of Market Access and Commercial Capabilities
Mamoru Sekiyama

Mamoru Sekiyama

Outside Director
Moyra Knight

Moyra Knight

Vice President, Corporate Communications President, Astellas Global Health Foundation
Show more

Astellas Pharma Office Locations

Astellas Pharma has offices in Tokyo, Takahagi, Takaoka, Toyama and in 57 other locations
Tokyo, JP (HQ)
2-5-1, Nihonbashi-Honcho, Chuo-ku
Takahagi, JP
160-2 Akahama
Takaoka, JP
30 Toidesakaemachi
Toyama, JP
2-178 Kōjinmachi
Tsukuba, JP
21 Miyukigaoka
Tsukuba, JP
21, Miyukigaoka
Show all (64)

Astellas Pharma Financials and Metrics

Astellas Pharma Revenue

Embed Graph
View revenue for all periods
Astellas Pharma's revenue was reported to be ¥1.3 t in FY, 2020 which is a 0.4% decrease from the previous period.
JPY

Revenue (H1, 2021)

615.5b

Gross profit (H1, 2021)

495.9b

Gross profit margin (H1, 2021), %

80.6%

Net income (H1, 2021)

72.8b

EBIT (H1, 2021)

86.9b

Market capitalization (21-Jul-2021)

3.5t

Closing stock price (21-Jul-2021)

1.9k

Cash (30-Sept-2020)

286.7b

EV

3.7t
Astellas Pharma's current market capitalization is ¥3.5 t.
Annual
JPYFY, 2018FY, 2019FY, 2020

Revenue

1.3t1.3t1.3t

Revenue growth, %

0%0%

Cost of goods sold

294.3b292.1b276.7b

Gross profit

1.0t1.0t1.0t
Half Year
JPYH1, 2019H1, 2020H1, 2021

Revenue

647.1b650.5b615.5b

Cost of goods sold

143.5b138.9b119.5b

Gross profit

503.6b511.6b495.9b

Gross profit Margin, %

78%79%81%
Annual
JPYFY, 2018FY, 2019FY, 2020

Cash

331.7b311.1b318.4b

Accounts Receivable

305.9b320.4b324.2b

Inventories

147.6b151.5b151.0b

Current Assets

845.6b857.2b867.5b
Quarterly
Annual
JPYFY, 2018FY, 2019FY, 2020

Depreciation and Amortization

64.9b63.5b66.4b

Inventories

37.8b5.5b(6.0b)

Accounts Payable

(43.8b)40.8b(21.4b)

Cash From Operating Activities

312.6b258.6b222.0b
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Depreciation and Amortization

16.1b31.8b47.8b17.0b31.1b48.3b18.0b35.9b

Inventories

2.4b3.6b2.0b(3.5b)(4.6b)(988.0m)(3.2b)(2.9b)

Accounts Payable

(5.9b)(11.4b)44.6b(45.0b)(24.5b)(42.7b)(30.2b)(50.8b)

Cash From Operating Activities

37.2b112.1b203.7b7.4b101.7b170.3b21.6b115.0b
JPYFY, 2018

Revenue/Employee

78.3m

Financial Leverage

1.5 x
Show all financial metrics

Astellas Pharma Operating Metrics

FY, 2020Oct, 2020

Phase I Trials Products (Immunology)

11

Phase I Trials Products (Oncology)

1

Phase II Trials Products (Oncology)

1

Phase III Trials Products (Oncology)

44
Show all operating metrics

Astellas Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Iota BiosciencesOctober 15, 2020$127.5 m
Nanna TherapeuticsApril 21, 2020£12 m
XyphosDecember 26, 2019
Audentes TherapeuticsDecember 02, 2019$3 b
Potenza TherapeuticsDecember 14, 2018$405 m
QuetheraAugust 14, 2018£85 m
Universal Cells Inc.February 13, 2018
MitobridgeDecember 01, 2017
OgedaApril 02, 2017€500 m
Ganymed PharmaceuticalsOctober 28, 2016$1.4 b
Show more

Astellas Pharma Revenue Breakdown

Embed Graph

Astellas Pharma revenue breakdown by business segment: 30.7% from XTANDI, 14.8% from Prograf, 12.4% from Betanis/Myrbetriq/BETMIGA and 42.0% from Other

Astellas Pharma revenue breakdown by geographic segment: 34.4% from United States , 28.8% from Japan and 36.7% from Other

Show all human capital metrics

Astellas Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Astellas Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Astellas Pharma Online and Social Media Presence

Embed Graph

Astellas Pharma Company Culture

  • Overall Culture

    F

    34/100

  • CEO Rating

    F

    30/100

  • Compensation

    F

    10/100

Learn more on Comparably

Astellas Pharma News and Updates

Global Stem Cell Therapy Market Report 2021-2030 Featuring Anterogen, JCR Pharma, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell

Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 provides the strategists, marke…

Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation

Astellas Venture Management (President: Kazunori Maruyama, Ph.D, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs ("MBC BioLabs"), a life-science incubator, today announced Keyhole Therapeutics, Inc. and Jupiter Therapeutics, Inc. as the winne…

KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus

KaliVir Immunotherapeutics LLC (CEO: Helena Chaye, Ph.D., J.D., “KaliVir”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that they entered into a worldwide licensing agreement for the research, development, and commercialization of VET2-L…

Astellas and Viatris Announce Termination of Co-promotion, Succession of Manufacturing and Marketing Approval, and Transfer of Distribution for Celecox® Tablets

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Viatris Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, “Viatris”) announced that the two companies have agreed to end the joint sales promotion (co-promotion) of the non-steroidal anti-inflammatory a…

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO® (roxadustat) for the treatment of anemia of chronic…

Astellas Transfers DIFICLIRTM in Europe, Middle East, Africa and selected CIS to Tillotts Pharma

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the subsidiary Astellas Pharma Europe Ltd. (“Astellas Europe”) and Tillotts Pharma AG (“Tillotts”) have entered into an Asset Purchase Agreement, under which Astellas Europe will transfer its…
Show more

Astellas Pharma Frequently Asked Questions

  • When was Astellas Pharma founded?

    Astellas Pharma was founded in 1923.

  • Who are Astellas Pharma key executives?

    Astellas Pharma's key executives are Yoshihiko Hatanaka, Shontelle Dodson and Kenji Yasukawa.

  • How many employees does Astellas Pharma have?

    Astellas Pharma has 15,883 employees.

  • What is Astellas Pharma revenue?

    Latest Astellas Pharma annual revenue is ¥1.3 t.

  • What is Astellas Pharma revenue per employee?

    Latest Astellas Pharma revenue per employee is ¥81.9 m.

  • Who are Astellas Pharma competitors?

    Competitors of Astellas Pharma include Nipro Corporation, Hetero and Viatris.

  • Where is Astellas Pharma headquarters?

    Astellas Pharma headquarters is located at 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo.

  • Where are Astellas Pharma offices?

    Astellas Pharma has offices in Tokyo, Takahagi, Takaoka, Toyama and in 57 other locations.

  • How many offices does Astellas Pharma have?

    Astellas Pharma has 64 offices.